At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 266 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
CP-690,550 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
In Brief
A Phase 3 clinical trial evaluating placebo and CP-690,550 for Psoriasis. Completed, enrolled 266 participants across 24 sites in 3 countries.
Detailed Summary
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartDec 2013
Primary CompletionJul 2015
TodayJul 2026
First PostedMar 21, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.3 years ago
Interventions
placebodrug
placebo BID for 16 weeks and then re-randomized into active groups
CP-690,550drug
CP-690,550 5mg BID for 52 weeks
CP-690,550drug
CP-690,550 10mg BID for 52 weeks